logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9566331 B1

PDFFull Text
Date of Patent:
Feb. 14, 2017

Filed:

Feb. 20, 2013

Vaccine immunotherapy

Applicant:

Irx Therapeutics, Inc., New York, NY (US);

Inventors:

John W. Hadden, Cold Spring Harbor, NY (US);

Kathy L. Signorelli, Kings Park, NY (US);

James E. Egan, Stony Brook, NY (US);

Paul H. Naylor, Lindenhurst, NY (US);

Assignee:

IRX Therapeutics, Inc., New York, NY (US);

Attorney:

Wolf, Greenfield & Sacks, P.C.

Primary Examiner:

Cherie M Stanfield

Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); A61K 38/16 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 38/164 (2013.01); A61K 38/177 (2013.01); A61K 38/191 (2013.01); A61K 38/193 (2013.01); A61K 38/204 (2013.01); A61K 38/2006 (2013.01); A61K 38/208 (2013.01); A61K 38/2013 (2013.01); A61K 38/2053 (2013.01); A61K 38/217 (2013.01); A61K 39/0011 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55588 (2013.01); A61K 2039/6081 (2013.01);
Abstract

A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.

Find Patent Forward Citations

Loading…